UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

Form 6-K

  

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2019

Commission File Number 001-38370

  

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

  

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

  

 

 

  

 

 

CollPlant Biotechnologies Ltd. hereby announces that it plans on releasing its interim financial statements for the period ended June 30, 2019 on or about September 26, 2019.

 

 1 

 

SIGNATURES  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  COLLPLANT BIOTECHNOLOGIES LTD.
Date: August 30, 2019 By:    /s/ Eran Rotem
    Name:  Eran Rotem
    Title: Deputy CEO and Chief Financial Officer

  

 2